1.
Klaus Geissler, Eva Jäger, Agnes Barna, Thamer Sliwa, Paul Knöbl, Ilse Schwarzinger, Heinz Gisslinger, Peter Valent. Is ruxolitinib a potentially useful drug in hematological malignancies with RAS pathway hyperactivation?. haematol [Internet]. 2016Nov.30 [cited 2024Jul.22];101(12):e492-e492. Available from: https://haematologica.org/article/view/7925